About CatalYm
CatalYm develops immune therapies for solid tumors. It identifies GDF-15 as a key cancer therapy resistance mechanism and aims to neutralize it. CatalYm's lead antibody, Visugromab, is in clinical trials for patients with relapsed and refractory metastatic solid tumors. The company focuses on advancing its therapies through clinical development.
Company Details
Corporate & Operational Profile
Web & Domain Identity
Social & Network Presence
Company Milestones & Timeline
- Capital Raise
Raised $150,000,000 · Series-B+
fundraisingfox.com
- Capital Raise
Raised $50,000,000 · Series-B+
- Capital Raise
Raised $59,040,000 · Series-B+
- Milestone
Website domain registered
catalym.com
Investors & Backers
Funding History
Founders & Leadership
Andrea Goddard
Chief Technology Officer
Anne Burger
CFO
Christine Schuberth Wagner
Chief Scientific Officer (CSO)
Clinton Musil
Chief Financial Officer and Chief Business Officer
Jörg Wischhusen
Founder
Peter Garcia
Chief Financial Officer
Phil L’Huillier
Managing Director and Chief Executive Officer (CEO)
Sujata Rao
Chief Medical Officer
Press Coverage & Sources
fundraisingfox.com/companies/catalym
endpts.com/german-biotech-catalym-raises-50m-to-build-phii-program-in-solid-tumors-expand-trial-in-us/
apnews.com/press-release/globe-newswire/business-technology-small-business-products-and-services-investment-management-21c693b1819e478fe136c346ccf78d4b
Recently Funded Biotech & Healthcare Startups
View allVitalls
vitalls.ai
Hexagon Bio
hexagonbio.com
RefloDx
reflodx.com
HeyVoli
heyvoli.com
CureBay
curebay.com
4Tissue
4tissue.com